Alizapride

DB01425InvestigationalSmall molecule

Alizapride is a dopamine antagonist used to prevent nausea and vomiting associated with medical procedures, surgeries, and cancer therapies. Alizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects.

Mechanism: The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)—this action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other atributres related to emesis and prokinetics.
Curator reviewed
Primary indication: Alizapride is used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.Curator reviewed · 4 structured indications
Formula / weight: C₁₆H₂₁N₅O₂ · 315.3702 g/mol (avg)

Resolves to

Compound

UNIIP55703ZRZYCAS59338-93-1ChEMBLCHEMBL290194ChEBI94316PubChem43008

Clinical / RWD

RxNorm17311ATCA03FA05PharmGKBPA164744894

Structure

InChIKeyKSEYRUGYKHXGFW-UHFFFAOYSA-NSMILESCOC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C

Targets

P14416DRD2

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

26Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

4Structured indicationsCondition, population, route and combination as fields, not prose

5ContraindicationsEach with its own population and attribute set

25Marketed productsAcross 2 countries and 9 labellers

1ATC codeIncluding every combination product, plus 10 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alizapride, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In